Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.

Literature DB >> 27324442

ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.

Seppo Ylä-Herttuala.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27324442 PMCID： PMC4923335 DOI： 10.1038/mt.2016.98

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

× No keyword cloud information.

7 in total

1. Oncolytic Treatment for Cancer Recommended for Approval.

Authors: Yuman Fong
Journal: Mol Ther Date: 2015-07 Impact factor: 11.454

2. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union.

Authors: Seppo Ylä-Herttuala
Journal: Mol Ther Date: 2012-10 Impact factor: 11.454

3. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.

Authors: M Onodera; T Ariga; N Kawamura; I Kobayashi; M Ohtsu; M Yamada; A Tame; H Furuta; M Okano; S Matsumoto; H Kotani; G J McGarrity; R M Blaese; Y Sakiyama
Journal: Blood Date: 1998-01-01 Impact factor: 22.113

4. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors: Alessandro Aiuti; Federica Cattaneo; Stefania Galimberti; Ulrike Benninghoff; Barbara Cassani; Luciano Callegaro; Samantha Scaramuzza; Grazia Andolfi; Massimiliano Mirolo; Immacolata Brigida; Antonella Tabucchi; Filippo Carlucci; Martha Eibl; Memet Aker; Shimon Slavin; Hamoud Al-Mousa; Abdulaziz Al Ghonaium; Alina Ferster; Andrea Duppenthaler; Luigi Notarangelo; Uwe Wintergerst; Rebecca H Buckley; Marco Bregni; Sarah Marktel; Maria Grazia Valsecchi; Paolo Rossi; Fabio Ciceri; Roberto Miniero; Claudio Bordignon; Maria-Grazia Roncarolo
Journal: N Engl J Med Date: 2009-01-29 Impact factor: 91.245

5. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors: R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal: Science Date: 1995-10-20 Impact factor: 47.728

6. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.

Authors: D B Kohn; M S Hershfield; D Carbonaro; A Shigeoka; J Brooks; E M Smogorzewska; L W Barsky; R Chan; F Burotto; G Annett; J A Nolta; G Crooks; N Kapoor; M Elder; D Wara; T Bowen; E Madsen; F F Snyder; J Bastian; L Muul; R M Blaese; K Weinberg; R Parkman
Journal: Nat Med Date: 1998-07 Impact factor: 53.440

7. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.

Authors: C Bordignon; L D Notarangelo; N Nobili; G Ferrari; G Casorati; P Panina; E Mazzolari; D Maggioni; C Rossi; P Servida; A G Ugazio; F Mavilio
Journal: Science Date: 1995-10-20 Impact factor: 47.728

7 in total

10 in total

1. Showcasing Clinical Development and Production of Cellular Therapies.

Authors: Bruce L Levine; Andrew D Fesnak; Isabelle Riviere
Journal: Mol Ther Date: 2017-03-22 Impact factor: 11.454

2. Perspectives on Manufacturing of High-Quality Cell Therapies.

Authors: Isabelle Rivière; Krishnendu Roy
Journal: Mol Ther Date: 2017-04-24 Impact factor: 11.454

Review 3. The Landscape of Early Clinical Gene Therapies outside of Oncology.

Authors: Laure Rittié; Takis Athanasopoulos; Miguel Calero-Garcia; Marie L Davies; David J Dow; Steven J Howe; Alastair Morrison; Ida Ricciardelli; Aurore Saudemont; Laurent Jespers; Timothy M Clay
Journal: Mol Ther Date: 2019-09-06 Impact factor: 11.454

ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.

1. Oncolytic Treatment for Cancer Recommended for Approval.

2. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union.

3. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.

4. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

5. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

6. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.

7. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.

1. Showcasing Clinical Development and Production of Cellular Therapies.

2. Perspectives on Manufacturing of High-Quality Cell Therapies.

Review 3. The Landscape of Early Clinical Gene Therapies outside of Oncology.

4. Production and Use of Gesicles for Nucleic Acid Delivery.

Review 5. Reconstructing the immune system with lentiviral vectors.

6. Delivery of large transgene cassettes by foamy virus vector.

Review 7. Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

8. Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers.

Review 9. Bioinformatics in translational drug discovery.

Review 10. Polymers in the Delivery of siRNA for the Treatment of Virus Infections.